- In 2Q 2016, Raptor expects to conduct a second interim analysis after 12 patients have completed 24 weeks of treatment.
Catalyst
Slingshot members are tracking this event:
Phase 2 second interim analysis of RP 103 for Mitochondial disorders including Leigh syndrome due 1Q 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| RPTP | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 05, 2016
Occurred Source:
http://ir.raptorpharma.com/releasedetail.cfm?ReleaseID=969545
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Interim, Rp 103, Mitochondial Disorders, Leigh Syndrome, 1q, Phase 2
